Why It Matters

Independence Blue Cross LLC filed an amended lobbying disclosure for the third quarter of 2025, reporting $170,000 in in-house lobbying activity. The filing arrives just days after the company's director of financial investigations testified before Congress on Medicare fraud.

The expiration of enhanced Affordable Care Act premium tax credits, sweeping Medicaid cuts under the One Big Beautiful Bill Act, and ongoing Medicare Advantage regulatory changes all carry direct financial consequences for the insurer. The Philadelphia-based insurer reported a $423 million net loss in 2025, driven by rising hospital, pharmacy, and surgical costs. Against that backdrop, its lobbying activity reflects an effort to shape federal health policy at a moment when the rules governing its core business lines are in flux.

By the Numbers: Lobbying Disclosure History

Independence Blue Cross is a well-established presence in congressional lobbying records. Across 11 filings dating back to mid-2024, the company has reported a combined $3,650,000 in lobbying expenditures, all conducted in-house.

The third quarter 2025 amended filing reports $170,000. That figure is consistent with the company's second quarter 2025 report ($160,000) and its third quarter 2025 report ($160,000), but significantly lower than the fourth quarter 2025 amended filing ($670,000) and the first quarter 2025 amendment ($740,000). The company also filed a separate second quarter 2025 amendment on the same date, also reporting $170,000.

The lobbying team has remained consistent throughout. Two in-house lobbyists handle all activity:

  • Jovi Hammer, who previously served as a professional staff member on the Senate Homeland Security and Governmental Affairs Committee and as a subcommittee director on the House Homeland Security Committee.
  • Mitch Vidovich, who previously served as a regional director for Sen. Patrick Toomey (R-PA).

Both lobbyists appear across all 11 filings in the company's recent lobbying activity report history, indicating a stable, long-running in-house operation rather than a reliance on outside firms.

The Agenda: What the Lobbying Activity Report Covers

The third quarter 2025 amended filing does not list specific issues or legislation. However, other recent filings from the same period provide a detailed picture of the company's lobbying agenda.

Across its recent lobbyist filings, Independence Blue Cross has consistently lobbied on:

  • ACA marketplace stability, including the extension of enhanced premium tax credits and individual market policy reforms
  • Medicare Advantage policy, including payment reform, CMS methodology improvements, and program implementation
  • Rx drug pricing and pharmacy benefit manager reforms
  • Site neutral payment reform and enhanced oversight of hospital and provider billing practices
  • Veterans health care, specifically supporting new care coordination with the VA
  • TRICARE competitive plan demonstration, seeking regional support from the Pennsylvania delegation
  • Defined pension benefit reform and flexibility of 401(h) retiree health plans
  • Privacy and cybersecurity issues specific to health plan data

No specific legislation is cited in any of the company's recent filings.

Broader Context: Medicare Fraud Hearing and Congressional Scrutiny

On April 21, 2026, Christopher Deery, Independence Blue Cross's director of corporate and financial investigations, testified before the House Ways and Means Committee at a full committee hearing titled "Protecting Patients and Taxpayers: Cracking Down on Medicare Fraud."

In his testimony, Deery described the company's fraud detection operations, saying "We analyze claims data on a daily basis, leveraging machine learning and other data analytic techniques, as well as payment dashboards to identify and flag suspicious patterns as they emerge."

He also flagged structural barriers that complicate fraud prevention. "While payers like Independence Blue Cross have invested heavily in advanced analytics, provider monitoring, and clinical validation, we continue to face structural barriers, and data sharing remains constrained by regulatory and operational limitations that can slow the timely exchange of actionable information."

Deery outlined three policy recommendations for improving fraud detection in traditional Medicare, including a shift to proactive monitoring, enhanced prepayment review, and better coordination among payers at all levels of government.

Two members of Congress specifically highlighted the testimony in their public communications. Rep. Aaron Bean (R-FL-4) posted about questioning Deery on Medicare's "pay-and-chase" system, noting that "by design, it puts the government at a disadvantage." Rep. Brian K. Fitzpatrick (R-PA-1), who represents a district in Independence Blue Cross's home region, also highlighted his exchange with Deery, calling Medicare fraud "not just theft from taxpayers."

Separately, the expiration of enhanced ACA premium tax credits has drawn significant congressional attention. Rep. Lauren Underwood (D-IL-14) cited a 27 percent rate increase from a Blue Cross affiliate as a direct consequence of Congress's failure to extend the credits. Sen. Richard Durbin (D-IL) wrote to major insurers, including Blue Cross Blue Shield, asking about the impact of the credit expiration, and described the response as describing "devastation."

The Bottom Line

Independence Blue Cross is a consistent, well-resourced player in federal health policy lobbying, operating entirely through in-house staff with deep congressional experience. The latest amended filing reflects an ongoing effort to engage on a broad set of health policy issues, even as the specific issues lobbied in this particular disclosure remain unlisted. The company's recent congressional testimony on Medicare fraud signals active engagement beyond traditional lobbying channels, positioning it as a participant in legislative discussions that could shape the regulatory environment for large regional insurers.

Access the Legis1 platform for comprehensive political news, data, and insights.